质谱尿液蛋白质组学鉴定幼年皮肌炎患者关键致病通路相关蛋白
该研究采用串联质谱标签尿液蛋白质组学方法,比较20例幼年皮肌炎(JDM)患者与21例健康对照的首晨尿,共检测到2348种蛋白,其中275种在所有样本中定量。组织蛋白酶D和半乳糖凝集素-3结合蛋白在JDM患者尿液中显著升高(校正P<0.05),并经ELISA验证;组织蛋白酶D与肌炎损害指数正相关(r=0.57,P<0.05),与儿童肌炎评估量表负相关(r=-0.54,P<0.05)。
要点
- JDM患者尿液组织蛋白酶D和半乳糖凝集素-3结合蛋白较健康对照显著升高(校正P<0.05),ELISA验证一致。
- 尿组织蛋白酶D与肌炎损害指数正相关(r=0.57,P<0.05),与儿童肌炎评估量表负相关(r=-0.54,P<0.05)。
- 研究还发现与细胞外基质重塑等肌炎关键特征相关的新型JDM候选生物标志物,原文指出需进一步验证。
核心结论
- 本研究证实JDM患者尿液中存在多种此前在肌炎患者血液中升高的蛋白,并发现需进一步验证的新型候选生物标志物。
- 结果支持将尿液作为JDM生物标志物开发的来源。
研究设计与样本
- 研究采集JDM患者(n=20)和健康对照(n=21)的首晨尿样本,采用标准化液相色谱-串联质谱方法分析。
- 差异显著改变的生物标志物与肌炎疾病活动度和损害临床指标进行相关性分析,部分候选标志物用市售ELISA试剂盒验证。
主要发现
- 样本中共检测到2348种蛋白,其中275种在所有样本中定量。
- 组织蛋白酶D和半乳糖凝集素-3结合蛋白在JDM患者尿液中显著升高(校正P<0.05),支持此前在肌炎患者中的发现,并经ELISA确认。
- 组织蛋白酶D与肌炎损害指数正相关(r=0.57,P<0.05),与儿童肌炎评估量表负相关(r=-0.54,P<0.05)。
- 研究还发现与肌炎关键特征相关的新型JDM候选生物标志物,包括细胞外基质重塑蛋白。
局限性
- 原文结论指出新发现的候选生物标志物需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify and validate biomarkers in JDM patients using a multiplexing tandem mass tag urine proteome profiling approach. METHODS: First morning void urine samples were collected from JDM patients (n = 20) and healthy control subjects (n = 21) and processed for analysis using a standardized liquid chromatography-tandem mass spectrometry approach. Biomarkers with significantly altered levels were correlated with clinical measures of myositis disease activity and damage. A subset of candidate biomarkers was validated using commercially available ELISA kits. RESULTS: In total, 2348 proteins were detected in the samples, with 275 proteins quantified across all samples. Among the differentially altered proteins, cathepsin D and galectin-3 binding protein were significantly increased in the urine of JDM patients (adjusted P < 0.05), supporting previous findings in myositis patients. These two candidate biomarkers were confirmed with ELISAs. Cathepsin D positively correlated with Myositis Damage Index (r = 0.57, P < 0.05) and negatively correlated with the Childhood Myositis Assessment Scale (r = -0.54, P < 0.05). We also identified novel JDM candidate biomarkers involved with key features of myositis, including extracellular matrix remodelling proteins. CONCLUSION: This study confirmed the presence of several proteins in the urine of JDM patients that were previously found to be elevated in the blood of myositis patients and identified novel candidate biomarkers that require validation. These results support the use of urine as a source for biomarker development in JDM.
引用
- Morales M, Alayi TD, Tawalbeh SM, et al. Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis. Rheumatology (Oxford). 2023. PMID: 36661295. doi:10.1093/rheumatology/kead033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。